Min Cui, Ph.D.

德诚资本 Managing Director

Dr. Min Cui is the Founder and Managing Director of Decheng Capital. At Decheng Capital, Dr. Cui has been focusing on partnerships with entrepreneurs and building biotechnology and medical technology companies in China and US. He is currently a board member of AccuraGen, Ariagen, ARMO BioSciences, CardioMed, EpimAb Biotherapeutics, GenapSys, GeneMDx, GRAIL (observer), Hummingbird Bioscience, Ketai Medical, Levitas, and SINOMED. His investment portfolio also includes 3SBio (HK Stock Exchange: 1530), China Biologic Products (NASDAQ: CBPO), Cirina (acquired by GRAIL), Epizyme (NASDAQ: EPZM), GeneWEAVE Biosciences (acquired by Roche), GenturaDx (acquired by Luminex), and Ion Torrent Systems (acquired by Life Technologies). Prior to founding Decheng Capital in 2011, Dr. Cui was an Investment Partner at Bay City Capital, a leading international life science venture capital firm in San Francisco. At Bay City, he led investment opportunities in US as well as all its initiatives in China. Dr. Cui was previously Director of Strategic Investment for the Southern Research Institute, an organization that discovered and developed six anti-cancer drugs that approved by the US Food and Drug Administration. Prior to that, Dr. Cui co-founded Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals, where he led efforts in discovery and development of several key technologies in the fields of oncology, cardiology, infectious and inflammatory diseases. Dr. Cui received his PhD in Cancer Biology from Stanford University and his BS and MS in Molecular Biology from Peking University. Dr. Cui was also a co-founder of CNetwork, a San Francisco based non-profit organization dedicated to serving Chinese communities in North America.

项目需求点击详情

• 投资行业偏好：
  医疗健康, 生物科技
• 行业细分说明：
  具有革命性的技术的早期生命科学公司和增长阶段的医疗保健公司
• 意向运营时间：
  1年内, 1-3年, 3-5年, 5年以上
• 意向运营阶段：
  产品开发, 上线初期, 增长期
• 偏好投资轮次：
  天使轮, pre-A轮, A轮, B轮, C轮
• 偏好投资金额：
  50-100万, 100-500万, 500-1000万, 1000-5000万, 5000万以上

上传商业计划书

Victor E. Tong, Jr.

德诚资本 Partner

Mr. Victor E. Tong, Jr. is a Partner at Decheng Capital and has been with the firm since its inception. At Decheng, Mr. Tong focuses on investments in biotechnology and medical technology companies in China and US. Mr. Tong currently serves on the boards of AccuraGen, EpimAb Biotherapeutics, GenapSys, GeneMDx, Levitas, ReadCoor and SentreHeart. He previously served on the boards of past Decheng companies Cirina (acquired by GRAIL) and GeneWEAVE Biosciences (acquired by Roche). Mr. Tong’s investment portfolio also includes 3SBio (1530.HK), Apexigen, ARMO Biosciences, Cellular Research (acquired by Becton Dickinson), China Biologic Products (NASDAQ: CBPO), Hummingbird Bioscience, Invitae (NASDAQ: NVTA) and SINOMED. Prior to joining Decheng, Mr. Tong was a Principal at Bay City Capital and was a member of the founding team of Nevro (NYSE: NVRO), a Bay City Capital-originated medical device company. He also played a key role in the firm’s investments in Cadence Pharmaceuticals (acquired by Mallinckrodt), GenturaDx (acquired by Luminex), Ion Torrent Systems (acquired by Life Technologies) and NextWave Pharmaceuticals (acquired by Pfizer). Prior to joining Bay City, Mr. Tong was an investment banker with Morgan Stanley, where he advised healthcare companies on initial public offerings and specialized in strategic advisory work. Prior to Morgan Stanley, Mr. Tong was an entrepreneur at Hana Biosciences (acquired by Spectrum Pharmaceuticals), where he was responsible for pipeline development, licensing and product launch for cancer products. Mr. Tong began his career participating in The Human Genome Project and its race to sequence the human genome as a research assistant at Incyte in 1999. Mr. Tong is a graduate of the University of California, Berkeley, where he earned a BA degree in Molecular and Cell Biology and a BS degree in Business Administration from the Haas School of Business.

项目需求点击详情

• 投资行业偏好：
  医疗健康, 生物科技
• 行业细分说明：
  具有革命性的技术的早期生命科学公司和增长阶段的医疗保健公司
• 意向运营时间：
  1年内, 1-3年, 3-5年, 5年以上
• 意向运营阶段：
  产品开发, 上线初期, 增长期
• 偏好投资轮次：
  天使轮, pre-A轮, A轮, B轮, C轮
• 偏好投资金额：
  50-100万, 100-500万, 500-1000万, 1000-5000万, 5000万以上

上传商业计划书

Qiang Xu, Ph.D.

德诚资本 Principal

Dr. Qiang Xu is a Principal at Decheng Capital and has been with the firm since its inception. He is currently serving on the boards of BCFoods and GYT HealthCare Services. He has over 14 years of experience from biotechnology start-ups to pharmaceutical companies and also has extensive experience in agricultural biotechnology. He was most recently Vice President of Research at Osel and the principal investigator for multiple grants funded by the NIH and other foundations. Dr. Xu started his biotechnology career at Bayer, worked at Pan Pacific Pharmaceuticals as a director, and Scios as a member of the Alzheimers Disease Discovery Program. He has published over 30 peer reviewed papers, and 50 conference presentations, and is the co-inventor of 10 patents or applications. Dr. Xu received his BS in agronomy and MS in Crop Sciences (with Professor Yu Songlie, an academician of the Chinese Academy of Engineering) and PhD in plant physiology from Kansas State University. He completed his postdoctoral training at the University of California, Berkeley.

项目需求点击详情

• 投资行业偏好：
  医疗健康, 生物科技
• 行业细分说明：
  具有革命性的技术的早期生命科学公司和增长阶段的医疗保健公司
• 意向运营时间：
  1年内, 1-3年, 3-5年, 5年以上
• 意向运营阶段：
  产品开发, 上线初期, 增长期
• 偏好投资轮次：
  天使轮, pre-A轮, A轮, B轮, C轮
• 偏好投资金额：
  50-100万, 100-500万, 500-1000万, 1000-5000万, 5000万以上

上传商业计划书

Nick Pliam, M.D., Ph.D.

德诚资本 Principal

Dr. Nick Pliam is a Principal at Decheng Capital. He has been with the firm since its inception and Bay City Capital since 2005. Dr. Pliam is trained as a cell biologist and orthopedic surgeon, and has worked within, and as an advisor to, biopharmaceutical and medical technology companies. He is a founder of Guided Delivery Systems, a medical device company developing a minimally invasive technology for treatment of mitral valve regurgitation, and a founder of Pharmagenesis, a natural products pharmaceutical company. As an independent consultant and as managing director of a boutique investment banking firm, he has advised life science companies and investors (including Biomet, Devax, Hanwha Pharmaceutical, Marubeni Group, Micrus Endovascular, and Triage Medical) on financing transactions and strategy. He is an inventor with patents in medical devices and biopharmaceuticals. Dr. Pliam serves on the boards of directors of Nevro Corporation (NYSE: NVRO) and a former member of the board of IDev Technologies (acquired by Abbott Laboratories). He holds an MD from Dartmouth Medical School and a PhD in Endocrine Physiology from the University of California, San Francisco. Dr. Pliam completed his surgical training at UCSF and Stanford University. He completed his undergraduate degree in German literature from the University of California, Berkeley, and studied at Georg August Universitaet in Goettingen.

项目需求点击详情

• 投资行业偏好：
  医疗健康, 生物科技
• 行业细分说明：
  具有革命性的技术的早期生命科学公司和增长阶段的医疗保健公司
• 意向运营时间：
  1年内, 1-3年, 3-5年, 5年以上
• 意向运营阶段：
  产品开发, 上线初期, 增长期
• 偏好投资轮次：
  天使轮, pre-A轮, A轮, B轮, C轮
• 偏好投资金额：
  50-100万, 100-500万, 500-1000万, 1000-5000万, 5000万以上

上传商业计划书

Tony Tong, Ph.D.

德诚资本 Vice President

Dr. Tony Tong is a Vice President of Decheng Capital and has been with the firm since May 2014. He has an interest in diverse sectors within the China healthcare industry. He currently serves on the boards of CardiMED and Insight Lifetech. Prior to joining Decheng Capital, Dr. Tong was a Vice President at Mingly China Growth Fund (MCGF), focusing on evaluating investment opportunities in the healthcare sector and serving on the boards of Yocaly (acquired by Lepu Medical), Family of Health (partially acquired by Sunshine Insurance), Sonicmed and Baifendian Technology. From 2009 to 2012, Dr. Tong was Senior Investment Associate at Yifang Ventures, a venture capital investment and asset management firm founded by Dr. Eric Xu, the Co-founder of Baidu.com. Dr. Tong received his PhD in Biochemistry and Molecular Biology from Institute of Biophysics of Chinese Academy of Science, a BS degree in Life Science from University of Science and Technology of China and the second BS degree in Economics from Peking University.

项目需求点击详情

• 投资行业偏好：
  医疗健康, 生物科技
• 行业细分说明：
  具有革命性的技术的早期生命科学公司和增长阶段的医疗保健公司
• 意向运营时间：
  1年内, 1-3年, 3-5年, 5年以上
• 意向运营阶段：
  产品开发, 上线初期, 增长期
• 偏好投资轮次：
  天使轮, pre-A轮, A轮, B轮, C轮
• 偏好投资金额：
  50-100万, 100-500万, 500-1000万, 1000-5000万, 5000万以上

上传商业计划书

钟鸿钧

儒艺资本 创始合伙人

牛津大学经济学博士，上海财经大学商学院战略与经济学教授； 10年商学教育经验，上海AMT管理咨询特聘专家。

项目需求点击详情

• 投资行业偏好：
  教育培训, 文体娱乐, 信息技术
• 行业细分说明：
  立足文娱、教育和互联网领域。
• 意向运营时间：
  1年内, 1-3年
• 意向运营阶段：
  产品开发, 上线初期, 增长期
• 偏好投资轮次：
  天使轮, pre-A轮, A轮, B轮, C轮
• 偏好投资金额：
  50-100万, 100-500万, 500-1000万, 1000-5000万

上传商业计划书

赵敏君

儒艺资本 创始合伙人

伦敦大学学院法学硕士；资深投资人，成功投资宅米、快收、Mustlisten等初创项目。

项目需求点击详情

• 投资行业偏好：
  教育培训, 文体娱乐, 信息技术
• 行业细分说明：
  立足文娱、教育和互联网领域。
• 意向运营时间：
  1年内, 1-3年
• 意向运营阶段：
  产品开发, 上线初期, 增长期
• 偏好投资轮次：
  天使轮, pre-A轮, A轮, B轮, C轮
• 偏好投资金额：
  50-100万, 100-500万, 500-1000万, 1000-5000万

上传商业计划书

欧阳鲲

方和资本 创始合伙人

方和资本创始合伙人 专注于互联网及媒体方向的投资。 欧阳先生在创立方和资本前，曾任IDG媒体基金合伙人，主导了多家知名互联网及文化媒体企业的投资，包括 Legendary Pictures（传奇影业）、Bilibili.tv、昆仑决、轻松筹等TMT公司。在加入IDG之前，他曾供职于摩根大通、工银瑞信基金和大成基金，具有11年的投资经验。欧阳鲲先生拥有美国麻省理工学院MBA学位，以及中央财经大学金融学士学位。

项目需求点击详情

• 投资行业偏好：
  金融支付, 移动互联网, 医疗健康, 文体娱乐, 互联网, 信息技术, 生物科技
• 行业细分说明：
  方和资本专注于互联网、消费升级、医疗、金融科技等新兴领域 前沿科技 互联网 消费升级 医疗
• 意向运营时间：
  1年内, 1-3年, 3-5年
• 意向运营阶段：
  产品开发, 上线初期, 增长期
• 偏好投资轮次：
  pre-A轮, A轮, B轮, C轮
• 偏好投资金额：
  50-100万, 100-500万, 500-1000万, 1000-5000万
• 详细需求说明：
  A轮到C轮是我们的投资阶段。

上传商业计划书

张岱

方和资本 创始合伙人

博士，方和资本创始合伙人，专注于医药健康和生命科学领域的投资。在创立方和资本之前，作为IDG资本医疗健康领域投资的主要负责人，主导了多家医疗健康企业的投资，包括体外诊断、创新药、介入医疗器械、生命科学试剂及高端医疗服务等；在加入IDG之前，张岱任职于瑞士信贷和Atlas Venture。张岱拥有中国医学科学院北京协和医学院医学遗传学博士学位和中国医科大学英文临床医学学位，并且分别在卫生部北京医院完成住院医生培训和对外经贸大学国际商学院完成MBA课程。

项目需求点击详情

• 投资行业偏好：
  金融支付, 移动互联网, 医疗健康, 文体娱乐, 互联网, 信息技术, 生物科技
• 行业细分说明：
  方和资本专注于互联网、消费升级、医疗、金融科技等新兴领域 前沿科技 互联网 消费升级 医疗
• 意向运营时间：
  1年内, 1-3年, 3-5年
• 意向运营阶段：
  产品开发, 上线初期, 增长期
• 偏好投资轮次：
  pre-A轮, A轮, B轮, C轮
• 偏好投资金额：
  50-100万, 100-500万, 500-1000万, 1000-5000万
• 详细需求说明：
  A轮到C轮是我们的投资阶段。

上传商业计划书

仉天颖

方和资本 管理合伙人

仉天颖专注于移动互联网、消费、金融及电商等领域的投资。加入方和资本前就职于小米科技战略投资部，担任投资总监，负责金融及海外投资，其投资的项目包括积木盒子、51信用卡、老虎证券等。她还曾就职于易凯资本，作为项目负责人完成包括瑞尔齿科、顺电、好孩子等多个项目的融资。仉天颖拥有英国纽卡斯尔大学金融与会计学硕士学位，以及中央财经大学会计学学士学位。

项目需求点击详情

• 投资行业偏好：
  金融支付, 移动互联网, 医疗健康, 文体娱乐, 互联网, 信息技术, 生物科技
• 行业细分说明：
  方和资本专注于互联网、消费升级、医疗、金融科技等新兴领域 前沿科技 互联网 消费升级 医疗
• 意向运营时间：
  1年内, 1-3年, 3-5年
• 意向运营阶段：
  产品开发, 上线初期, 增长期
• 偏好投资轮次：
  pre-A轮, A轮, B轮, C轮
• 偏好投资金额：
  50-100万, 100-500万, 500-1000万, 1000-5000万
• 详细需求说明：
  A轮到C轮是我们的投资阶段。

上传商业计划书

沈皓澄

方和资本 管理合伙人

沈皓澄侧重于IoT, 人工智能及企业服务、消费金融领域的投资。加入方和资本前，曾进行过多次互联网创业，他是西游帮金融的早期创始人及北美留学生日报的联合创始人。回国前沈皓澄还曾任职于美国花旗集团全球技术部。他在互联网及在业界的丰富工作经历使得他对技术及市场的关系有着深刻的见解，能够抓住互联网和尖端科技的最新动向。他大学期间曾专注于计算机及人工智能相关的研究并发表多篇成果。沈皓澄毕业于美国康奈尔大学，并获得计算机科学学士学位。

项目需求点击详情

• 投资行业偏好：
  金融支付, 移动互联网, 医疗健康, 文体娱乐, 互联网, 信息技术, 生物科技
• 行业细分说明：
  方和资本专注于互联网、消费升级、医疗、金融科技等新兴领域 前沿科技 互联网 消费升级 医疗
• 意向运营时间：
  1年内, 1-3年, 3-5年
• 意向运营阶段：
  产品开发, 上线初期, 增长期
• 偏好投资轮次：
  pre-A轮, A轮, B轮, C轮
• 偏好投资金额：
  50-100万, 100-500万, 500-1000万, 1000-5000万
• 详细需求说明：
  A轮到C轮是我们的投资阶段。

上传商业计划书

陈启宇

复星同浩/星未来 董事长&管理合伙人

陈启宇先生是复星集团执行总裁、复星医药董事长兼复星同浩资本董事长。陈先生同时是国药控股非执行董事兼副董事长及浙江迪安诊断董事。 陈启宇先生现为中国医药物资协会会长、中国医药工业科研开发促进会副会长、中国医药生物技术协会副理事长、中国化学制药工业协会副会长、上海生物医药行业协会会长及上海市遗传学会副理事长。 陈启宇先生拥有中欧国际工商学院高级工商管理硕士学位和复旦大学遗传学学士学位

项目需求点击详情

• 投资行业偏好：
  金融支付, 移动互联网, 医疗健康, 教育培训, 高新科技, 文体娱乐, 软件, 硬件, 互联网, 电商, 信息技术, 餐饮酒店, 游戏, 媒体营销, 跨界服务, 其他行业, 生物科技, 旅游
• 行业细分说明：
  同浩资本聚焦医疗健康和TMT高科技领域
• 意向运营时间：
  1年内, 1-3年, 3-5年, 5年以上
• 意向运营阶段：
  产品开发, 上线初期, 增长期, 稳定盈利, 快速扩张
• 偏好投资轮次：
  天使轮, pre-A轮, A轮, B轮, C轮
• 偏好投资金额：
  50-100万, 100-500万, 500-1000万, 1000-5000万, 5000万以上
• 详细需求说明：
  投资阶段覆盖天使和A、B轮，C轮以后项目酌情跟进，单个项目投资金额从几百万到数千万人民币不等。

上传商业计划书